RxDoctor Payments Data

Thang Pham, PA

Physician Assistant · Glendale, CANPI 1295207447

Payments from drug & device makers

$10,012in general payments, 2019–2025

Across 467 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Boehringer Ingelheim$956
  • AstraZeneca$915
  • Merck$891
  • Amgen$839
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$724
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$10,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,012 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$82,464
Medicare patients
665
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$173,372
CamzyosMavacamten13$109,412
EntrestoSacubitril/Valsartan126$105,646
Repatha SureclickEvolocumab51$37,408
FarxigaDapagliflozin Propanediol41$34,762
JardianceEmpagliflozin47$29,863
XareltoRivaroxaban22$21,176
VerquvoVericiguat11$12,398
VascepaIcosapent Ethyl13$5,923
Telmisartan122$3,057
Rosuvastatin Calcium253$3,024
Ranolazine ErRanolazine27$3,002
Metoprolol Succinate253$2,417
Nebivolol Hcl28$2,387
Isosorbide Mononitrate ErIsosorbide Mononitrate86$1,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$95$173,372179 claims
E.r. Squibb & Sons, L.L.C.Camzyos$24$109,41213 claims
NovartisEntresto$1,608$105,646126 claims
AstraZenecaFarxiga$915$34,76241 claims
Boehringer IngelheimJardiance$956$29,86347 claims
Johnson & JohnsonXarelto$287$21,17622 claims
MerckVerquvo$891$12,39811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →